Skip to content

PRO-AF 52: Monthly Primary-Care 12-Lead ECG Screening for Incident Atrial Fibrillation in Adults Aged ≥65 Years

A Prospective, Single-Group, Primary-Care-Based 12-Lead ECG Screening Program With 12-Month Follow-up for Incident Atrial Fibrillation and Guideline-Directed Oral Anticoagulation in Ordu, Türkiye (PRO-AF 52)

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07438054
Acronym
PRO-AF 52
Enrollment
1000
Registered
2026-02-27
Start date
2026-01-01
Completion date
2027-12-31
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation (AF)

Keywords

ECG screening, primary care, older adults, oral anticoagulation, adherence, stroke, bleeding

Brief summary

This prospective, single-arm study will evaluate the feasibility and yield of monthly, in-clinic 12-lead electrocardiogram (ECG) screening performed at affiliated Family Health Centers (Aile Sağlığı Merkezleri; ASMs) in Ordu, Türkiye, among community-dwelling adults aged ≥65 years without a prior diagnosis of atrial fibrillation (AF). Each participant will be followed for 12 months (12 visits). New AF will be confirmed on ASM-acquired 12-lead ECG and managed by the tertiary Cardiology Department according to contemporary guidelines, including initiation of oral anticoagulation (OAC) when indicated. Outcomes include incident AF detection, OAC initiation and adherence, and ischemic/hemorrhagic clinical events.

Detailed description

Participants aged ≥65 years registered at participating ASMs will undergo monthly standard resting 12-lead ECGs captured on site by trained primary-care staff. All ECGs will be centrally reviewed and reported by cardiologists from the tertiary Cardiology Department. ECG is the only screening/diagnostic tool in the protocol; no wearable/photoplethysmography (PPG) devices or ambulatory patches are used. Participants with newly detected AF will be referred to the tertiary Cardiology Department for guideline-directed care. Decisions regarding OAC initiation, dosing, drug choice, bleeding risk mitigation, and follow-up are made by cardiology as part of routine clinical practice. Participants with sinus rhythm on ASM ECG but palpitations or related symptoms will also be evaluated by cardiology; any additional tests (e.g., Holter monitoring) are outside the study interventions and performed as usual care. At each monthly visit, study staff will capture symptoms, vitals, medications, adverse events, and an ECG. Endpoint events will be source-verified (hospital records, imaging, discharge summaries) and adjudicated by a blinded outcomes committee. Visit windows are ±7 days.

Interventions

DIAGNOSTIC_TESTMonthly 12-lead ECG

Standard resting 12-lead ECG performed at each monthly visit (12 visits over 12 months), centrally interpreted by cardiologists. No wearable/PPG devices or ambulatory patches are used in the protocol

Sponsors

Kotyora Family Medicine Health Management and Education Association
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥65 years. * Registered at a participating Family Health Center (ASM) in Ordu, Türkiye, with expected availability for 12 months of follow-up. * Able to provide written informed consent

Exclusion criteria

* Prior diagnosis of atrial fibrillation or atrial flutter. * Long-term therapeutic anticoagulation for any indication at baseline. * Residence in long-term care, hospice, or palliative status. * Enrollment in another interventional study that conflicts with the protocol. * Planning to relocate or otherwise unable to attend monthly visits.

Design outcomes

Primary

MeasureTime frameDescription
Incident AF detection rateBaseline through Month 12Proportion of participants with new AF confirmed on ASM-acquired 12-lead ECG during 12-month follow-up.

Secondary

MeasureTime frame
Time to OAC initiation among incident AFAF diagnosis to OAC start within 90 days
OAC adherence (MPR ≥80%)Months 1-12 after OAC start
Ischemic events (ischemic stroke, TIA, systemic embolism)Baseline to Month 12
Hemorrhagic events (ISTH major bleeding; clinically relevant non-major bleeding)Baseline to Month 12
All-cause hospitalizationBaseline to Month 12
Net clinical outcome (ischemic stroke/TIA/systemic embolism, ISTH major bleeding, all-cause death)Baseline to Month 12

Countries

Turkey (Türkiye)

Contacts

STUDY_CHAIRSeçkin Dereli, MD, Assoc. Prof.

Ordu University Faculty of Medicine, Department of Cardiology (Turkey)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026